Eli Lilly and Company (NYSE: LLY) beats the adjusted EPS consensus of approx. $8.89 in Q2 2026 earnings (August 5, 2026, before market open)
Miss
✦ AI-generated prediction
Published on 20. July 2026
·
Predicted for 5. August 2026
·
Based on: Historical Cycle
Eli Lilly reports Q2 2026 on August 5 before market open. EPS consensus is approx. $8.89/share (Meyka/TipRanks); revenue consensus is $20.5B. Structural driver: GLP-1 demand for Mounjaro (diabetes) and Zepbound (obesity) remains relentless; Lilly is market leader in the fast-growing incretin segment. Lilly has consistently beaten estimates in recent quarters. Risk factors: incretin production capacity constraints; potential US drug pricing pressure (IRA implementation). No Polymarket odds found; beat probability structurally high.
Data basis for this prediction
- Meyka.com: LLY Q2 2026 Ergebnis erwartet 5. August vor Marktöffnung (meyka.com, Stand Juli 2026)
- TipRanks/Meyka: EPS-Konsens Q2 2026 ca. 8,89 USD; Umsatz-Konsens 20,50 Mrd. USD
- SEC EDGAR: Eli Lilly Form 8-K FY2026 Q1 – als Referenz für Wachstumstraj. (sec.gov)
- Public.com/LLY: Lilly Earnings History – konsistente Beats (Stand Juli 2026)
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Miss
Eli Lilly meldete am 5. August 2026 vor Marktöffnung ein bereinigtes EPS von 8,38 USD für Q2 2026 – was unterhalb des in der Vorhersage genannten Konsens-Schwellenwerts von ca. 8,89 USD liegt. Die Vorhersage ist daher gemäß ihrem eigenen Maßstab verfehlt. Ursache: Der in der Vorhersage verwendete Konsens-EPS (~8,89 USD, Meyka/TipRanks) war deutlich zu hoch angesetzt – der tatsächliche Analysten-Konsens lag laut Alphastreet/CNBC bei ca. 6,01–6,55 USD je Aktie. Diesen echten Konsens schlug Lilly massiv (~+30–40 %). Umsatz: 22,97 Mrd. USD (+48 % yoy), ebenfalls weit über Konsens (~20,5 Mrd. USD). Quellen: Lilly Investor Relations (investor.lilly.com), PR Newswire (prnewswire.com/news-releases/302843165), Alphastreet (news.alphastreet.com/eli-lilly-and-company-lly-q2-2026-preview-eps-est-6-55-reports-august-5), CNBC (cnbc.com/2026/08/05/eli-lilly-lly-earnings-q2-2026).
📈 Economy
✦ AI
The S&P 500 closed at 7,636.36 on 9 September 2026. Falling below 7,450 by month-end would require a 2.4% decline. Headwinds: Fed rate hike of 25bp on 16 September (CentralBank.Watch: 59% probability), August PPI above expectations (+5.4% YoY), Iran-Gulf risk premium. Stabilizing factors: hike largely priced in (Polymarket: 93% for zero 2026 cuts), Q2 earnings solid, no recession signals. Historically, a single 25bp September hike rarely causes a monthly decline above 2.5%.
📈 Economy
✦ AI
Polymarket shows a 53% probability for a 25 basis point hike as of September 10, 2026. US Core CPI August 2026 (release September 11) is expected by market consensus to be above 3.0% YoY. The ECB raised its deposit rate by 25 bps to 2.50% on September 10, 2026 – an inflation-fighting signal that provides cover for the Fed. Against a hike: a mild slowdown in US industrial output. CME FedWatch also shows ~53% probability for a hike.
📈 Economy
✦ AI
The DAX closed at 25,562 points on September 9, 2026. A gain of +1.7% is required by month-end. Headwinds: ECB rate hike to 2.50% (September 10), 53% FOMC hike probability (September 16), persistently high oil prices (~$101/barrel Brent) weigh on energy-intensive DAX heavyweights. Tailwinds: strong SAP cloud growth expected, robust US demand, EUR/USD at 1.1644 benefits exporters. Implied 30-day volatility (VDAX): ~16%, corresponding to a σ range of roughly ±5.5% by month-end — the 26,000 level falls within the central distribution.